Trial Site News
Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
  • Register
  • Log In
  • News
  • Video
  • Podcast
  • More
Trial Site News
  • News For You
  • Op-Eds
  • Video
  • Podcasts
  • Investor Watch
  • Write for us
  • News for You
  • Op-Eds
  • Video
  • Podcasts
  • Covid-19
  • Investor Watch

Topic: Acute Respiratory Distress Syndrome

Novartis Pays $50m Upfront Cash for License and Stock in Mesoblast to Access Mesenchymal Stromal Cells Regenerative Therapy Platform

Novartis recently inked an exclusive worldwide license and collaboration agreement with regenerative therapy venture Mesoblast to develop, commercialize and manufacture […]

Novartis Pays $50m Upfront Cash for License and Stock in Mesoblast to Access Mesenchymal Stromal Cells Regenerative Therapy Platform
3 months ago
Share

FDA Approves EC-18 for Phase 2 Clinical Trials Targeting ARDS in COVID-19 Patients: Led by Duke Infectious Disease Expert Dr. Cameron Robert Wolfe

South Korean-based Enzychem Lifesciences (KOSDAQ: 183490) just announced that the US Food and Drug Administration (FDA) has accepted its Investigational […]

FDA Approves EC-18 for Phase 2 Clinical Trials Targeting ARDS in COVID-19 Patients: Led by Duke Infectious Disease Expert Dr. Cameron Robert Wolfe
7 months ago
Share

UCI Investigates Synthetic Vasoactive Intestinal Polypeptide-based Experimental Drug on High Risk SARS-CoV-2 Patients

University of California Irvine, (UCI) recently announced their participation in a COVID-19-focused clinical trial investigating a drug called Aviptadil in […]

UCI Investigates Synthetic Vasoactive Intestinal Polypeptide-based Experimental Drug on High Risk SARS-CoV-2 Patients
10 months ago
Share

Mount Sinai Leading a Clinical Trial Evaluating Allogeneic Stem Cell Therapy on COVID-19 ARDS Patients

Mount Sinai Health System will be conducting a study using remestemcel-L (Ryoncil), an innovative allogeneic stem cell therapy in patients […]

Mount Sinai Leading a Clinical Trial Evaluating Allogeneic Stem Cell Therapy on COVID-19 ARDS Patients
11 months ago
Share

Glangwili Hospital Doctor Develops Improved Ventilator for Severe COVID-19 Cases

Wales doesn’t necessarily make international news often, despite its cultural richness, serene beauty and legacy of intelligent inventors. But it […]

Glangwili Hospital Doctor Develops Improved Ventilator for Severe COVID-19 Cases
11 months ago
Share

The FDA Approving Experimental Stem Cell Therapies Targeting Patients with Severe COVID-19 Cases

Novel medical innovations are being pursued by biotech companies and clinical investigators to halt COVID-19 causalities as there is, presently, […]

The FDA Approving Experimental Stem Cell Therapies Targeting Patients with Severe COVID-19 Cases
11 months ago
Share

Austrian Biotech’s Investigational Phase II Drug Receives Compassionate Use Approval for COVID-19 ARDS

About 20% of those hospitalized with COVID-19 suffer from acute respiratory distress syndrome (ARDS), a potentially life-threatening complication of the […]

Austrian Biotech’s Investigational Phase II Drug Receives Compassionate Use Approval for COVID-19 ARDS
11 months ago
Share

Latest Podcasts

Alan Cannell talks COVID-19: Nobody Likes Cheap Solutions | Podcast S2 E41

Dr. Pierre Kory Talks Covid-19, Ivermectin and the FLCCC | Podcast E43

An Interview With Patricia Carter: Patient Engagement and Retention in Clinical Trials

Dr. Negin Hajizadeh: Researchers Finding A Very Effective Treatment For Covid-19 In New Study

Dr. Jean-Jacques Rajter and Dr. Juliana Cepelowicz Rajter Discuss Ivermectin In Broward County | Podcast S2 E 27

159 W Broadway, Suite 200
Salt Lake City, UT 84101

[email protected]

Connect With Us

TRIALSITE NEWS IS THE ONLY DIGITAL MEDIA DEDICATED 100% TO TRANSPARENT AND OPEN COVERAGE OF CLINICAL RESEARCH TRIAL SITES AROUND THE GLOBE. BASED IN THE SILICON SLOPES IN DOWNTOWN SALT LAKE CITY, UTAH, WE ARE FOUNDED BY A TEAM OF EXPERTS IN THE CLINICAL TRIALS INDUSTRY AND DEDICATED TO TRANSPARENCY, QUALITY AND CLINICAL TRIAL INNOVATION.

© 2021 TRIALSITE NEWS. ALL RIGHTS RESERVED.